Abbrea Capital’s Alnylam Pharmaceuticals ALNY Stock Holding History

Abbrea Capital’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-1,425	Closed	-$213K	–	227
2024 Q1	$213K	Hold	1,425	–	–	0.03%	241
2023 Q4	$273K	Hold	1,425	–	–	0.04%	207
2023 Q3	$252K	Hold	1,425	–	–	0.04%	207
2023 Q2	$271K	Hold	1,425	–	–	0.04%	202
2023 Q1	$285K	Sell	1,425 -150	-10%	-$31.5K	0.05%	194
2022 Q4	$374K	Hold	1,575	–	–	0.07%	172
2022 Q3	$315K	Hold	1,575	–	–	0.06%	174
2022 Q2	$230K	Hold	1,575	–	–	0.04%	211
2022 Q1	$257K	Hold	1,575	–	–	0.04%	221
2021 Q4	$267K	Hold	1,575	–	–	0.04%	218
2021 Q3	$297K	Hold	1,575	–	–	0.04%	206
2021 Q2	$267K	Hold	1,575	–	–	0.04%	214
2021 Q1	$222K	Buy	+1,575	New	+$237K	0.04%	215

Other funds holding ALNY

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Abbrea Capital's ALNY Position: Q2 2024 in Review

Abbrea Capital sold out of Alnylam Pharmaceuticals (ALNY) in Q2 2024, closing a stake of 1,425 shares — an estimated $213K sold.

Abbrea Capital first reported a position in ALNY in Q1 2021 and held it in 13 quarters. The position peaked at $374K in Q4 2022. 523 funds tracked by Wall St. Rank hold ALNY as of Q2 2024.

Abbrea Capital reported no remaining Alnylam Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
Abbrea Capital sold 1,425 Alnylam Pharmaceuticals shares in Q2 2024, an estimated $213K.
Abbrea Capital first reported a position in Alnylam Pharmaceuticals in Q1 2021 and held it in 13 quarters.
Abbrea Capital's Alnylam Pharmaceuticals position peaked at $374K in Q4 2022.
523 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2024.

Based on Abbrea Capital's 13F filing for Q2 2024, filed 8 Aug 2024.